BCD INNOVATIONS - Key Persons

Job Titles:

• Vice President of Investor Relations
• Vice President of Investor Relations of BCD Innovations, Inc

Angela Mah has worked in both private and public sectors (including Fortune 500 companies and Harvard School of Public Health) holding leadership positions in the area of executive management, global business development, media and public relations for the past 25 years. As the Vice President of Investor Relations of BCD Innovations, Inc., Ms. Mah manages relationships with the investor community for ensuring the company is strategically positioned with investors and all stakeholders locally and in Asia. Prior to BCD Innovations, Ms. Mah was the Consultant of client relations of Massachusetts Growth Capital Corporation, Ms. Mah provided guidance and leadership to a team of client service members on state level relief grants and loan programs serving over 10,000 small businesses in Massachusetts. Prior to joining MGCC, Ms. Mah was the Vice President of Global Business Development at InTeahouse, Inc. She led over 20 successful global summits in life sciences, cleantech, fintech and robotic technologies. Leading U.S. companies to find investors, strategic partners and new market opportunities in China, Israel, Germany and U.K. Ms. Mah also served in various executive positions prior in financial institutions including Bank of America, Santander Bank, and United Commercial Bank and Harvard School of Public Health.

Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division and Professor of Oncology, Otolaryngology, Genetics and Pathology at Johns Hopkins University School of Medicine. He has served as Chairman of the Board of Directors of Champions Oncology since October 2007 and was, until the merger with Eli Lilly, a Director and Vice-Chairman of ImClone Systems, Inc. He is the Chairman of Tamir Biotechnology and serves on the Board of Directors of Rosetta Genomics, Immune Pharmaceuticals and Celsus. He is serving and has served on scientific advisory boards of MedImmune, Roche, Amgen and Veridex, LLC (a Johnson & Johnson diagnostic company), among others. Dr. Sidransky served as Director (2005-2008) of the American Association for Cancer Research (AACR).

Job Titles:

• Advisor
• Psychiatry Specialist

Dr. Maxie Gordon is a Psychiatry Specialist in Clinton, Mississippi. He graduated with honors from Meharry Medical College School Of Medicine in 1995. Having more than 25 years of diverse experiences, especially in PSYCHIATRY, INTERNAL MEDICINE, Dr. Maxie Gordon affiliates with St Dominic-jackson Memorial Hospital, cooperates with many other doctors and specialists in many medical groups including Region Vi Mental Health / Mental Retardation Commission, Warren Yazoo Mental Health Service, Miracle Care Home Services LLC, Maxie Gordon Md And Associates,

Job Titles:

• Director, NCI, Innovator for BCG - Co - Chairman of Science Advisory Board

Dr. Michael G Hanna, Jr. received his PhD in experimental pathology and immunology from the University of Tennessee (TN, USA) in the 1960s. He was a consultant with NASA for the lunar receiv- ing laboratory during Apollo 11 and 12, for which his expertise in immunology was used in the test- ing of the lunar core powder for immunogenic or pathogenic materials. Dr. Hanna served during 1974-83 as Director of the National Cancer Institute, Frederick Cancer Research Center (MD, USA). He was Chief Operating Officer during 1985-94 of Organon Teknika/Biotechnology Research Institute and Senior Vice President of Organon Teknika Corporation, a subsidiary of Akzo Nobel, Netherlands. He developed and obtained approvals for TICE BCG for the treatment of carcinoma in situ (CIS) bladder cancer, which remains the standard of care for prophylaxis of recurrence of superficial bladder cancer and therapy of CIS. Subsequently, Dr. Hanna founded PerImmune Inc., for which he served as President and Chief Executive Officer before it merged with Intracel Corp. in 1998. He continued to work for Intracel Resources as Chief Scientific Officer and Chairman. In 2007, Dr. Hanna founded Vaccinogen Inc., where he served as Chairman and CEO. Currently, Dr. Hanna is Chairman Emeritus. The company is a pioneer in the field of cancer vaccines and is developing OncoVAX, an autologous vaccine designed to elicit a specific immune response against cancer cells. The Phase 3 vaccine is being investigated for treatment mainly of colon cancer, but also for melanoma and renal cell carcinoma. Dr. Hanna's research resulted in over 225 publications in international peer-reviewed journals and book chapters, and he holds 10 patents related to immunotherapy. Dr. Hanna has been the recipient of numerous honors and awards and has served on many editorial boards, including for Human Vaccines & Immunotherapeutics.

Job Titles:

• Independent Consultant
• Senior Business Adviser Natixis Bleichroder, World Bank, Lazard

Mario Gobbo is an independent consultant since 2010 when he was head of life sciences equity capital markets and M&A for Natixis Bleichroeder, a boutique investment bank in New York, which he had joined in 2006. He has 35 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as investment banking and strategic advisory. He is on the board of Zavarovalnica Triglav, the largest Slovene insurance company spearheading healthcare insurance in Central Europe and was Chairman of the Board and Chair of the Audit Committee of Helix BioPharma, a Toronto listed biotech company developing interesting novel complex biomolecules to combat various cancers. When with Natixis Bleichroeder, he obtained mandates for several IPOs and follow-on transactions on NASDAQ, as well as advisory assignments for health care and medical devices companies. With International Finance Corporation, a World Bank Group institution dealing with private sector investments, the team he led completed several highly successful equity and loan investments in biotech and generic pharmaceutical companies and funds in India, Latin America, China and Central Europe. From 1993 to 2001, he was with Lazard in London, where he created and managed their Central and Eastern European operations. As an executive director, he sat on the Lazard Brothers Board in London. He advised on M&A, fundraising and privatization efforts for several key firms in the region, including transactions for the pharmaceutical companies Pliva, Bosnalijek, Lek and Krka. Prior to Lazard, he worked with Swiss Bank Corporation International Ltd. in London, where he worked on the IPO of Ares Serono, the Swiss biotech company, subsequently sold to Merck KgaA. He was also on the investment committee of AHF, an India focused health care fund, Ocimum Biosolutions/Genelogic, an Indian contract research organization, and CellPraxis, a US/Brazilian stem cell research, privately owned firm. He holds a BA with a major in Organic Chemistry from Harvard College, a Master of Science in Biochemistry from the University of Colorado and an MBA, a Master of Business Economics and a PhD (Management) from the Wharton School of the University of Pennsylvania. And currently resides in Chevy chase, Maryland.

Job Titles:

• Global CEO
• Global Chief Executive Officer

Michael Chan is the Global CEO of BCD Innovations whose leadership and multidimensional expertise will help shape the future of BCD to positively impact the biotech industry. Having more than 20 years of experience in finance, regulatory work, and as senior executive at Hong Kong Exchanges and Clearing Limited (HKEX), Michael has a deep understand of the intricate workings of the financial industry. His experience in regulatory oversight and as well as global market development work have instilled in him an unparalleled understanding of compliance requirements and a high standard of risk management ensuring that BCD attains to the highest standards. Beyond his regulatory experience, Michael has actively contributed to market development initiatives, playing a pivotal role in shaping the success of the HKEX biotech landscape becoming one of the world's most vibrant and active biotech fund raising hub. His strategic vision and keen business acumen have enabled him to identify emerging trends, drive sustainable growth and forge strategic partnerships. As a seasoned speaker, Michael has shared his insights on numerous global platforms with the ability to articulate complex matters in a clear and engaging manner. Furthermore, Michael brings significant financial experience, having advised many prominent institutions, organisations and biotech companies, particularly on investment strategies, group structures, capital allocations, attracting investors, securing funding and optimising performances. Michael, having been a regulator, is also a strong advocate for compliance and regulatory integrity bringing unwavering commitment to ethical practices and the ability to navigate complex compliance landscapes ensuring the highest standards of governance and risk management. With this extraordinary blend of regulatory expertise, global market development track record success, financial acumen and compliance work, Michael is driving forward BCD Innovation's vision and the mission to positively impact the global healthcare landscape.

Job Titles:

• Advisor
• Managing Director of GrayBella Capital LLC

Richard Kivel serves as Managing Director of GrayBella Capital LLC., a VC/PE investment fund focused on biotech, healthcare and technology companies in Europe. Richard has served as a CEO, Chairman and Board Director in both private and public companies in Europe, Russia, Singapore and the US.